Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 506 participants.

Also called NCT05027074

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 506 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05027074
  • EU CT 2024-511055-17-00
  • WHO UTN U1111-1303-0286
  • EudraCT 2020-002397-27
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Brazil, Bulgaria, Canada, Czechia, Germany, Greece, Italy, Portugal, Puerto Rico, Romania, Russia, Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05027074. Randomized; quadruple masking; primary purpose prevention. Start 2021-09-17 (actual); primary completion 2024-10-30 (actual). Results posted on 2025-11-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
Condition
End-Stage Renal Disease
Condition
End-Stage Kidney Disease
Condition
Kidney Failure, Chronic
Intervention (Drug)
MK-2060
Intervention (Drug)
Placebo
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct05027074
Content hash
14c6cb032b53b3310165d419f2bf4783b826dd894fd83392a0fd24a58b375431